Kidney Fibrosis Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.

The global market for Kidney Fibrosis Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Kidney Fibrosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Kidney Fibrosis Treatment by region & country, by Type, and by Application.

The Kidney Fibrosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Fibrosis Treatment.

Market Segmentation

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Kidney Fibrosis Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Kidney Fibrosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Kidney Fibrosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

 1 Market Overview
    1.1 Kidney Fibrosis Treatment Product Introduction
    1.2 Global Kidney Fibrosis Treatment Market Size Forecast
    1.3 Kidney Fibrosis Treatment Market Trends & Drivers
        1.3.1 Kidney Fibrosis Treatment Industry Trends
        1.3.2 Kidney Fibrosis Treatment Market Drivers & Opportunity
        1.3.3 Kidney Fibrosis Treatment Market Challenges
        1.3.4 Kidney Fibrosis Treatment Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Kidney Fibrosis Treatment Players Revenue Ranking (2023)
    2.2 Global Kidney Fibrosis Treatment Revenue by Company (2019-2024)
    2.3 Key Companies Kidney Fibrosis Treatment Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Kidney Fibrosis Treatment Product Offered
    2.5 Key Companies Time to Begin Mass Production of Kidney Fibrosis Treatment
    2.6 Kidney Fibrosis Treatment Market Competitive Analysis
        2.6.1 Kidney Fibrosis Treatment Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Kidney Fibrosis Treatment Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Fibrosis Treatment as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Angiotensin Converting Enzyme (ACE) Inhibitors
        3.1.2 Pirfenidone
        3.1.3 Renin Inhibitors
        3.1.4 Angiotensin II Receptor Blockers (ARBs)
        3.1.5 Vasopeptidase Inhibitors
    3.2 Global Kidney Fibrosis Treatment Sales Value by Type
        3.2.1 Global Kidney Fibrosis Treatment Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Kidney Fibrosis Treatment Sales Value, by Type (2019-2030)
        3.2.3 Global Kidney Fibrosis Treatment Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Chronic Kidney Diseases
        4.1.2 Kidney Cancer Treatment
        4.1.3 Others
    4.2 Global Kidney Fibrosis Treatment Sales Value by Application
        4.2.1 Global Kidney Fibrosis Treatment Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Kidney Fibrosis Treatment Sales Value, by Application (2019-2030)
        4.2.3 Global Kidney Fibrosis Treatment Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Kidney Fibrosis Treatment Sales Value by Region
        5.1.1 Global Kidney Fibrosis Treatment Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Kidney Fibrosis Treatment Sales Value by Region (2019-2024)
        5.1.3 Global Kidney Fibrosis Treatment Sales Value by Region (2025-2030)
        5.1.4 Global Kidney Fibrosis Treatment Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Kidney Fibrosis Treatment Sales Value, 2019-2030
        5.2.2 North America Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Kidney Fibrosis Treatment Sales Value, 2019-2030
        5.3.2 Europe Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Kidney Fibrosis Treatment Sales Value, 2019-2030
        5.4.2 Asia Pacific Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Kidney Fibrosis Treatment Sales Value, 2019-2030
        5.5.2 South America Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Kidney Fibrosis Treatment Sales Value, 2019-2030
        5.6.2 Middle East & Africa Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Kidney Fibrosis Treatment Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Kidney Fibrosis Treatment Sales Value
    6.3 United States
        6.3.1 United States Kidney Fibrosis Treatment Sales Value, 2019-2030
        6.3.2 United States Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Kidney Fibrosis Treatment Sales Value, 2019-2030
        6.4.2 Europe Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Kidney Fibrosis Treatment Sales Value, 2019-2030
        6.5.2 China Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Kidney Fibrosis Treatment Sales Value, 2019-2030
        6.6.2 Japan Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Kidney Fibrosis Treatment Sales Value, 2019-2030
        6.7.2 South Korea Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Kidney Fibrosis Treatment Sales Value, 2019-2030
        6.8.2 Southeast Asia Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Kidney Fibrosis Treatment Sales Value, 2019-2030
        6.9.2 India Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Kidney Fibrosis Treatment Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Merck and Co(US)
        7.1.1 Merck and Co(US) Profile
        7.1.2 Merck and Co(US) Main Business
        7.1.3 Merck and Co(US) Kidney Fibrosis Treatment Products, Services and Solutions
        7.1.4 Merck and Co(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
        7.1.5 Merck and Co(US) Recent Developments
    7.2 Pfizer Inc(US)
        7.2.1 Pfizer Inc(US) Profile
        7.2.2 Pfizer Inc(US) Main Business
        7.2.3 Pfizer Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions
        7.2.4 Pfizer Inc(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
        7.2.5 Pfizer Inc(US) Recent Developments
    7.3 F. Hoffman-La Roche(Switzerland)
        7.3.1 F. Hoffman-La Roche(Switzerland) Profile
        7.3.2 F. Hoffman-La Roche(Switzerland) Main Business
        7.3.3 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Products, Services and Solutions
        7.3.4 F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
        7.3.5 InterMune Inc(US) Recent Developments
    7.4 InterMune Inc(US)
        7.4.1 InterMune Inc(US) Profile
        7.4.2 InterMune Inc(US) Main Business
        7.4.3 InterMune Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions
        7.4.4 InterMune Inc(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
        7.4.5 InterMune Inc(US) Recent Developments
    7.5 Galectin Therapeutics(US)
        7.5.1 Galectin Therapeutics(US) Profile
        7.5.2 Galectin Therapeutics(US) Main Business
        7.5.3 Galectin Therapeutics(US) Kidney Fibrosis Treatment Products, Services and Solutions
        7.5.4 Galectin Therapeutics(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
        7.5.5 Galectin Therapeutics(US) Recent Developments
    7.6 La Jolla Pharmaceutical Company(US)
        7.6.1 La Jolla Pharmaceutical Company(US) Profile
        7.6.2 La Jolla Pharmaceutical Company(US) Main Business
        7.6.3 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Products, Services and Solutions
        7.6.4 La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
        7.6.5 La Jolla Pharmaceutical Company(US) Recent Developments
    7.7 ProMetic Life-Sciences Inc(Canada)
        7.7.1 ProMetic Life-Sciences Inc(Canada) Profile
        7.7.2 ProMetic Life-Sciences Inc(Canada) Main Business
        7.7.3 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Products, Services and Solutions
        7.7.4 ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
        7.7.5 ProMetic Life-Sciences Inc(Canada) Recent Developments
    7.8 BioLine Rx(Israel)
        7.8.1 BioLine Rx(Israel) Profile
        7.8.2 BioLine Rx(Israel) Main Business
        7.8.3 BioLine Rx(Israel) Kidney Fibrosis Treatment Products, Services and Solutions
        7.8.4 BioLine Rx(Israel) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
        7.8.5 BioLine Rx(Israel) Recent Developments
    7.9 Genzyme Corporation(US)
        7.9.1 Genzyme Corporation(US) Profile
        7.9.2 Genzyme Corporation(US) Main Business
        7.9.3 Genzyme Corporation(US) Kidney Fibrosis Treatment Products, Services and Solutions
        7.9.4 Genzyme Corporation(US) Kidney Fibrosis Treatment Revenue (US$ Million) & (2019-2024)
        7.9.5 Genzyme Corporation(US) Recent Developments

 8 Industry Chain Analysis
    8.1 Kidney Fibrosis Treatment Industrial Chain
    8.2 Kidney Fibrosis Treatment Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Kidney Fibrosis Treatment Sales Model
        8.5.2 Sales Channel
        8.5.3 Kidney Fibrosis Treatment Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

List of Tables
    Table 1. Kidney Fibrosis Treatment Market Trends
    Table 2. Kidney Fibrosis Treatment Market Drivers & Opportunity
    Table 3. Kidney Fibrosis Treatment Market Challenges
    Table 4. Kidney Fibrosis Treatment Market Restraints
    Table 5. Global Kidney Fibrosis Treatment Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Kidney Fibrosis Treatment Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Kidney Fibrosis Treatment Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Kidney Fibrosis Treatment Product Type
    Table 9. Key Companies Time to Begin Mass Production of Kidney Fibrosis Treatment
    Table 10. Global Kidney Fibrosis Treatment Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Fibrosis Treatment as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Kidney Fibrosis Treatment Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Kidney Fibrosis Treatment Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Kidney Fibrosis Treatment Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Kidney Fibrosis Treatment Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Kidney Fibrosis Treatment Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Kidney Fibrosis Treatment Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Kidney Fibrosis Treatment Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Kidney Fibrosis Treatment Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Kidney Fibrosis Treatment Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Kidney Fibrosis Treatment Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Kidney Fibrosis Treatment Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Kidney Fibrosis Treatment Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Kidney Fibrosis Treatment Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Kidney Fibrosis Treatment Sales Value by Region (2019-2024) & (%)
    Table 27. Global Kidney Fibrosis Treatment Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Kidney Fibrosis Treatment Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Kidney Fibrosis Treatment Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Kidney Fibrosis Treatment Sales Value, (2025-2030) & (US$ Million)
    Table 31. Merck and Co(US) Basic Information List
    Table 32. Merck and Co(US) Description and Business Overview
    Table 33. Merck and Co(US) Kidney Fibrosis Treatment Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of Merck and Co(US) (2019-2024)
    Table 35. Merck and Co(US) Recent Developments
    Table 36. Pfizer Inc(US) Basic Information List
    Table 37. Pfizer Inc(US) Description and Business Overview
    Table 38. Pfizer Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of Pfizer Inc(US) (2019-2024)
    Table 40. Pfizer Inc(US) Recent Developments
    Table 41. F. Hoffman-La Roche(Switzerland) Basic Information List
    Table 42. F. Hoffman-La Roche(Switzerland) Description and Business Overview
    Table 43. F. Hoffman-La Roche(Switzerland) Kidney Fibrosis Treatment Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of F. Hoffman-La Roche(Switzerland) (2019-2024)
    Table 45. F. Hoffman-La Roche(Switzerland) Recent Developments
    Table 46. InterMune Inc(US) Basic Information List
    Table 47. InterMune Inc(US) Description and Business Overview
    Table 48. InterMune Inc(US) Kidney Fibrosis Treatment Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of InterMune Inc(US) (2019-2024)
    Table 50. InterMune Inc(US) Recent Developments
    Table 51. Galectin Therapeutics(US) Basic Information List
    Table 52. Galectin Therapeutics(US) Description and Business Overview
    Table 53. Galectin Therapeutics(US) Kidney Fibrosis Treatment Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of Galectin Therapeutics(US) (2019-2024)
    Table 55. Galectin Therapeutics(US) Recent Developments
    Table 56. La Jolla Pharmaceutical Company(US) Basic Information List
    Table 57. La Jolla Pharmaceutical Company(US) Description and Business Overview
    Table 58. La Jolla Pharmaceutical Company(US) Kidney Fibrosis Treatment Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of La Jolla Pharmaceutical Company(US) (2019-2024)
    Table 60. La Jolla Pharmaceutical Company(US) Recent Developments
    Table 61. ProMetic Life-Sciences Inc(Canada) Basic Information List
    Table 62. ProMetic Life-Sciences Inc(Canada) Description and Business Overview
    Table 63. ProMetic Life-Sciences Inc(Canada) Kidney Fibrosis Treatment Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of ProMetic Life-Sciences Inc(Canada) (2019-2024)
    Table 65. ProMetic Life-Sciences Inc(Canada) Recent Developments
    Table 66. BioLine Rx(Israel) Basic Information List
    Table 67. BioLine Rx(Israel) Description and Business Overview
    Table 68. BioLine Rx(Israel) Kidney Fibrosis Treatment Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of BioLine Rx(Israel) (2019-2024)
    Table 70. BioLine Rx(Israel) Recent Developments
    Table 71. Genzyme Corporation(US) Basic Information List
    Table 72. Genzyme Corporation(US) Description and Business Overview
    Table 73. Genzyme Corporation(US) Kidney Fibrosis Treatment Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Kidney Fibrosis Treatment Business of Genzyme Corporation(US) (2019-2024)
    Table 75. Genzyme Corporation(US) Recent Developments
    Table 76. Key Raw Materials Lists
    Table 77. Raw Materials Key Suppliers Lists
    Table 78. Kidney Fibrosis Treatment Downstream Customers
    Table 79. Kidney Fibrosis Treatment Distributors List
    Table 80. Research Programs/Design for This Report
    Table 81. Key Data Information from Secondary Sources
    Table 82. Key Data Information from Primary Sources
    Table 83. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Kidney Fibrosis Treatment Product Picture
    Figure 2. Global Kidney Fibrosis Treatment Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 4. Kidney Fibrosis Treatment Report Years Considered
    Figure 5. Global Kidney Fibrosis Treatment Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Kidney Fibrosis Treatment Revenue in 2023
    Figure 7. Kidney Fibrosis Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Angiotensin Converting Enzyme (ACE) Inhibitors Picture
    Figure 9. Pirfenidone Picture
    Figure 10. Renin Inhibitors Picture
    Figure 11. Angiotensin II Receptor Blockers (ARBs) Picture
    Figure 12. Vasopeptidase Inhibitors Picture
    Figure 13. Global Kidney Fibrosis Treatment Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 14. Global Kidney Fibrosis Treatment Sales Value Market Share by Type, 2023 & 2030
    Figure 15. Product Picture of Chronic Kidney Diseases
    Figure 16. Product Picture of Kidney Cancer Treatment
    Figure 17. Product Picture of Others
    Figure 18. Global Kidney Fibrosis Treatment Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 19. Global Kidney Fibrosis Treatment Sales Value Market Share by Application, 2023 & 2030
    Figure 20. North America Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 21. North America Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 22. Europe Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 23. Europe Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 24. Asia Pacific Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 25. Asia Pacific Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 26. South America Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 27. South America Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 28. Middle East & Africa Kidney Fibrosis Treatment Sales Value (2019-2030) & (US$ Million)
    Figure 29. Middle East & Africa Kidney Fibrosis Treatment Sales Value by Country (%), 2023 VS 2030
    Figure 30. Key Countries/Regions Kidney Fibrosis Treatment Sales Value (%), (2019-2030)
    Figure 31. United States Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 32. United States Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 33. United States Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 34. Europe Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 35. Europe Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 36. Europe Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 37. China Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 38. China Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 39. China Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 40. Japan Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 41. Japan Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 42. Japan Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 43. South Korea Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 44. South Korea Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 45. South Korea Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 46. Southeast Asia Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Southeast Asia Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 48. Southeast Asia Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 49. India Kidney Fibrosis Treatment Sales Value, (2019-2030) & (US$ Million)
    Figure 50. India Kidney Fibrosis Treatment Sales Value by Type (%), 2023 VS 2030
    Figure 51. India Kidney Fibrosis Treatment Sales Value by Application (%), 2023 VS 2030
    Figure 52. Kidney Fibrosis Treatment Industrial Chain
    Figure 53. Kidney Fibrosis Treatment Manufacturing Cost Structure
    Figure 54. Channels of Distribution (Direct Sales, and Distribution)
    Figure 55. Bottom-up and Top-down Approaches for This Report
    Figure 56. Data Triangulation

Kidney or renal fibrosis is the body process from which the kidney’s excess fibrous connective tissue or organs takes its formation repetitively.

The global market for Kidney Fibrosis Treatment was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Kidney Fibrosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Kidney Fibrosis Treatment by region & country, by Type, and by Application.

The Kidney Fibrosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Fibrosis Treatment.

Market Segmentation

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Kidney Fibrosis Treatment manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Kidney Fibrosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Kidney Fibrosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.